HonorStocks Biotech Gold Oil Mining China Asian MENU
Biotech Gold Oil Mining China Asian
Find Tomorrow's Winners Today

Stock technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell neutral buy
Vertex Pharmaceuticals Incorporated (VRTX)
211.58  1.5  (0.71%) 10-25 06:49
Open: 212.19 High: 213.5
Pre.close: 210.08 Low: 209.07
Volume: 1,715,758 Ave vol: 1,676,746
52w High: 306.08 52w Low: 192.32
MA(50): 255.893 MA(200): 271.368
EPS: 7.923 P/E Ratio: 26.7
Company profile
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Website: https://www.vrtx.com/
Market Cap (M): 55,110
Shares Out (M): 260
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 2,500 full-time employees. The firm is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The firm's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The firm's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.
Technical analysis
Overall: Outperform
MA: Bearish MACD: Bearish
KDJ: Bullish RSI: Bullish
Target 1: 295.73 Target 2: 328.20
Resist 1: 253.20 Resist 2: 280.99
Support 1: 208.23 Support 2: 173.25
Company key metrics
Revenue per Share: 15.9695
Net Income per Share: 4.5145
Cash per Share: 11.9281
Book Value per Share: 23.3444
Price to Sales: 14.4219
Price to Book Value: 9.8658
Earnings Yield: 0.0196
Dividend Yield: 0
Debt to Equity: 0.367
Debt to Assets: 0.2685
Financial analysis
Price to Book Value: Outperform
Return on Assets: Neutral
Return on Equity: Outperform
Discounted cash flow: Outperform
Price to Earnings: Outperform
Debt to Equity: Neutral
Stock Charts

HonorStocks, Find Tomorrow's Winners Today

©HonorStocks.com | U.S. stock markets, stock quotes and stock analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither HonorStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX and Financial Modeling Prep

Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Google's use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.